Cytovac

Executive Summary

Cytovac is a Danish biotechnology company developing novel oncolytic virus-based cancer immunotherapies. Its approach uses engineered viruses to selectively target and destroy tumor cells while stimulating a systemic anti-tumor immune response. Founded in 2014 and headquartered in Copenhagen, the company is private and operates in the cell & gene therapy space. The platform is designed to address multiple solid tumor indications, potentially offering a differentiated mechanism combining direct oncolysis with immune activation. Cytovac's technology has the potential to overcome key limitations of current immunotherapies, such as limited tumor infiltration and immune evasion. However, as a private early-stage company with no disclosed funding rounds or clinical milestones, the risk profile remains high. The company's progression depends on securing financing and advancing its lead candidates into clinical trials. If successful, Cytovac could become a significant player in the oncolytic virus field, a market expected to grow substantially as combination strategies with checkpoint inhibitors gain traction.

Upcoming Catalysts (preview)

• Q4 2026Lead Program IND Filing40% success
• Q2 2027Series A Financing Round60% success
• Q1 2027First-in-Human Trial Initiation35% success